Cell-Free Synthetic Bacteriophage Assembly for Broad Host Range
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complexity of modifying bacteriophages for therapeutic applications is hindered by the difficulty in altering their genomes, and conventional antibiotics are ineffective against multi-drug resistant bacteria strains like MRSA, necessitating a safer and more efficient production method for bacteriophages.
Innovation Solution
The development of multi-peptide structures composed of homologous peptides differing by at least one amino acid, which are self-assembled in a cell-free expression system, allowing for the production of synthetic bacteriophages with enhanced host specificity and lytic efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional methods are used to modify bacteriophage genomes for therapeutic applications, then the bacteriophages can be produced, but the complexity of modification increases significantly due to the difficulty of altering bacteriophage genomes
Solution Approach 1:
The bacteriophage genome is divided into separate expression cassettes that can be independently modified and assembled. Each cassette contains genes for specific structural proteins (capsid, tail fibers, etc.), allowing individual optimization of host specificity without requiring complex whole-genome manipulation. The segmented genome can be reassembled through standardized connection protocols.
Solution Approach 2:
A standardized intermediate assembly system is introduced between genome modification and functional bacteriophage production. This intermediary involves modular expression cassettes with universal connection interfaces (similar to LEGO blocks), which simplify the assembly process and reduce the technical complexity of genome modification while maintaining the ability to achieve specific host specificity.
2Productivity
If bacteriophages are produced using traditional methods, then they can be manufactured, but the process lacks safety controls and efficiency optimization
Solution Approach 1:
Safety and efficiency controls are built into the production process beforehand through standardized expression cassettes with predefined regulatory elements (promoters, terminators, ribosome binding sites). These preliminary design choices ensure consistent expression levels and proper protein folding, reducing variability and improving both productivity and reliability without requiring complex real-time monitoring.
Solution Approach 2:
The production process allows systematic optimization of expression parameters (promoter strength, codon usage, protein ratios) through standardized cassette design. By pre-establishing parameter ranges and optimization protocols, the system achieves high productivity while maintaining safety through controlled variable changes rather than uncontrolled trial-and-error approaches.
3Adaptability or versatility
If single-type bacteriophages are used for treatment, then they have specific targeting capability, but they risk developing resistance and have limited host range
Solution Approach 1:
Multiple expression cassettes encoding different bacteriophage types are combined in a single production system. The standardized assembly protocol allows co-expression of heterologous proteins from different bacteriophages, creating multi-functional particles that can target multiple bacterial hosts simultaneously. This merging approach expands host range while reducing resistance risk through diverse targeting mechanisms.
Solution Approach 2:
The expression system is designed with universal compatibility to produce multiple bacteriophage types using the same standardized cassettes and assembly protocols. This multi-functional platform allows a single production system to generate diverse bacteriophage compositions tailored to different bacterial threats, enhancing both host range and reliability through versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of synthetic bacteriophages with broad host range and high specificity, reducing the risk of resistance and side effects, making them effective alternatives to antibiotics for treating bacterial infections.
Implementation Method 1
adding nucleic acids encoding homologous bacteriophage proteins to the expression system; expressing the nucleic acids encoding the homologous proteins
Implementation Method 2
expressing the nucleic acids encoding the homologous proteins in the cell-free expression system to produce homologous bacteriophage proteins
Implementation Method 3
assembling of the expressed homologous proteins to provide the assembled multi-peptide structures; the expressed proteins self assemble to the inventive multi-peptide structure
Data Source
AI summary
The present invention relates to multi-peptide structures comprising at least one heterogenous functional site wherein the at least one heterogenous functional site is composed of at least two homologous peptides, which differ by at least one amino acid, a method for providing such multi-peptide structures, compositions comprising such multi-peptide structures as well as the use of such multi-peptide structures and compositions as an universal anti-microbial agent, in particular in medicine, chemistry, biotechnology, agriculture and/or food industry.